The co-expression characteristics of LAG3 and PD-1 on the T cells of patients with breast cancer reveal a new therapeutic strategy.
作者： Ziying Yi , Long Wang , Zhi Li , Bailin Niu , Guosheng Ren
DOI: 10.1016/J.INTIMP.2019.106113
关键词: Flow cytometry 、 Triple-negative breast cancer 、 Breast cancer 、 LAG3 、 Phenotype 、 MHC class II 、 T cell 、 Cancer research 、 Immunohistochemistry 、 Medicine
摘要: … that blocking LAG3 and PD-1 together can indeed induce stronger anti-tumour effects (Fig. 7). … Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A …
scilit.net参考文章(46)
Bonnie L. Phillips, Smriti Mehra, Muhammad H. Ahsan, Moises Selman, Shabaana A. Khader, Deepak Kaushal, LAG3 Expression in Active Mycobacterium tuberculosis Infections The American Journal of Pathology. ,vol. 185, pp. 820- 833 ,(2015) , 10.1016/J.AJPATH.2014.11.003
Linh T. Nguyen, Pamela S. Ohashi, Clinical blockade of PD1 and LAG3 — potential mechanisms of action Nature Reviews Immunology. ,vol. 15, pp. 45- 56 ,(2015) , 10.1038/NRI3790
Jens M. Chemnitz, Richard V. Parry, Kim E. Nichols, Carl H. June, James L. Riley, SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. Journal of Immunology. ,vol. 173, pp. 945- 954 ,(2004) , 10.4049/JIMMUNOL.173.2.945
Ruea-Yea Huang, Cheryl Eppolito, Shashikant Lele, Protul Shrikant, Junko Matsuzaki, Kunle Odunsi, LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model Oncotarget. ,vol. 6, pp. 27359- 27377 ,(2015) , 10.18632/ONCOTARGET.4751
Andres Forero, Yufeng Li, Dongquan Chen, William E. Grizzle, Katherine L. Updike, Natalie D. Merz, Erinn Downs-Kelly, Todd C. Burwell, Christos Vaklavas, Donald J. Buchsbaum, Richard M. Myers, Albert F. LoBuglio, Katherine E. Varley, Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes. Cancer immunology research. ,vol. 4, pp. 390- 399 ,(2016) , 10.1158/2326-6066.CIR-15-0243
Paula García-Teijido, María Luque Cabal, Ignacio Peláez Fernández, Yolanda Fernández Pérez, Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting Clinical Medicine Insights: Oncology. ,vol. 10, pp. 31- 39 ,(2016) , 10.4137/CMO.S34540
Michael J. Gray, Jian Gong, Michaela M. S. Hatch, Van Nguyen, Christopher C. W. Hughes, Jeff T. Hutchins, Bruce D. Freimark, Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers Breast Cancer Research. ,vol. 18, pp. 50- 50 ,(2016) , 10.1186/S13058-016-0708-2
Tomohiro Okagawa, Satoru Konnai, James R. Deringer, Massaro W. Ueti, Glen A. Scoles, Shiro Murata, Kazuhiko Ohashi, Wendy C. Brown, Cooperation of PD-1 and LAG-3 Contributes to T-Cell Exhaustion in Anaplasma marginale-Infected Cattle Infection and Immunity. ,vol. 84, pp. 2779- 2790 ,(2016) , 10.1128/IAI.00278-16
Giulia Bottai, Carlotta Raschioni, Agnese Losurdo, Luca Di Tommaso, Corrado Tinterri, Rosalba Torrisi, Jorge S. Reis-Filho, Massimo Roncalli, Christos Sotiriou, Armando Santoro, Alberto Mantovani, Sherene Loi, Libero Santarpia, An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers. Breast Cancer Research. ,vol. 18, pp. 121- 121 ,(2016) , 10.1186/S13058-016-0783-4
Julia Y. S. Tsang, Wai-Ling Au, Kwan-Yin Lo, Yun-Bi Ni, Thazin Hlaing, Jintao Hu, Siu-Ki Chan, Kui-Fat Chan, Sai-Yin Cheung, Gary M. Tse, PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients Breast Cancer Research and Treatment. ,vol. 162, pp. 19- 30 ,(2017) , 10.1007/S10549-016-4095-2